NCT01206933|Completed
Loading search results
Sponsor study identifier
observational
20
1 country
1
Study Start
July 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2015
Actual (reported)Study Completion
June 2015
Actual (reported)Investigators in the Division of Infectious Diseases and the Departments of Biochemistry and Molecular Biology of The George Washington University Medical Center are carrying out a research study to determine why patients with Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) co-infection (HIV/HCV) have a more rapid and progressive course of HCV infection, leading to fatty infiltration of the liver and cirrhosis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2015
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 2010
Date type not reportedThis date has not been verified as actual or estimated.
September 17, 2010
Actual (reported)September 22, 2010
Actual (reported)June 2015
Actual (reported)June 2015
Actual (reported)Laboratory analysis of Tat Protein
The validation that HIV Tat protein is a potent inducer of HCV in dual infected patients will likely lead to anti-tat therapy to manage HCV patients for whom treatment options are rather limited.
Single sample analysis
HIV and HCV co-infected with detectable HIV RNA and HCV RNA
HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA.
HIV and HCV infected, Undetectable HIV RNA and HCV RNA
HCV(mono-infected,) HCV RNA undetectable
Monoinfected HCV, detectable RNA
Monoinfected HIV, Detectable RNA
Four groups of subjects will be included in this study, with 5 participants in each group: 1. detectable HIV RNA (Ribonucleic Acid) and detectable HCV RNA 2. undetectable HIV RNA (treated) and detectable HCV RNA 3. undetectable HIV RNA (treated) and undetectable HCV RNA 4. undetectable HCV RNA (mono-infected) 5. detectable HCV RNA (mono-infected) 6. detectable HIV RNA (mono-infected)
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, 20037, United States
David Parenti, MD
George Washington University
20 participants (actual enrollment reported by the registry).
First Submitted
September 17, 2010
First Posted
September 22, 2010
Study Start
July 2010
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
June 2015
Actual (reported)Study Completion
June 2015
Actual (reported)Last Updated
February 10, 2016
Record last verified: 2010-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: